Literature DB >> 19164806

Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis.

Hanna Hlawaty1, Marie-Paule Jacob, Liliane Louedec, Didier Letourneur, Charles Brink, Jean-Baptiste Michel, Laurent Feldman, Magnus Bäck.   

Abstract

OBJECTIVE: The lipid-derived inflammatory mediators leukotrienes (LTs) are produced during vascular injury. The aim of the present study was to determine the role of LT receptor signaling in the pathophysiology of in-stent stenosis. METHODS AND
RESULTS: New Zealand White rabbits were fed 0.3% cholesterol and subjected to angioplasty with balloon dilatation and stent implantation in the right carotid artery. Rabbits treated for 2 weeks with the BLT receptor antagonist BIIL284 (3 mg/kg once daily by oral gavage) displayed a significantly reduced in-stent intimal hyperplasia in carotid arteries compared with vehicle-treated rabbits. In addition, BIIL284 treatment significantly reduced the extracellular matrix metalloproteinase (MMP)-2 and MMP-9 activities in stented arteries. The inhibited MMP-9 activity was correlated with decreased macrophage content in the lesions. The LTB(4)-induced migration of vascular smooth muscle cells was significantly inhibited by transfection with siRNA against MMP-2. Finally, human arteries subjected to ex vivo angioplasty and stent implantation displayed an increased in-stent intimal hyperplasia and higher MMP-2 and -9 activities in the presence of LTB(4).
CONCLUSIONS: These results suggest a key role of LT signaling in the extracellular matrix degradation associated with hyperlipidemia and in-stent stenosis. In conclusion, targeting LT receptors may represent a therapeutic strategy in atherosclerosis and interventional cardiology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164806     DOI: 10.1161/ATVBAHA.108.181750

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  14 in total

Review 1.  The role of matrix metalloproteinases in atherothrombosis.

Authors:  Daniel F J Ketelhuth; Magnus Bäck
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

Review 2.  Anti-inflammatory therapies for atherosclerosis.

Authors:  Magnus Bäck; Göran K Hansson
Journal:  Nat Rev Cardiol       Date:  2015-02-10       Impact factor: 32.419

3.  Leukotriene B4 receptor-1 mediates intermittent hypoxia-induced atherogenesis.

Authors:  Richard C Li; Bodduluri Haribabu; Steven P Mathis; Jinkwan Kim; David Gozal
Journal:  Am J Respir Crit Care Med       Date:  2011-04-14       Impact factor: 21.405

4.  Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea.

Authors:  Françoise Stanke-Labesque; Jean-Louis Pépin; Tiphaine de Jouvencel; Claire Arnaud; Jean-Philippe Baguet; Marcelo H Petri; Renaud Tamisier; Jean François Jourdil; Patrick Lévy; Magnus Bäck
Journal:  J Lipid Res       Date:  2012-07-03       Impact factor: 5.922

5.  Myeloid cell 5-lipoxygenase activating protein modulates the response to vascular injury.

Authors:  Zhou Yu; Emanuela Ricciotti; Takashi Miwa; Shulin Liu; Kaori Ihida-Stansbury; Gavin Landesberg; Peter L Jones; Rosario Scalia; Wen-Chao Song; Richard K Assoian; Garret A FitzGerald
Journal:  Circ Res       Date:  2012-12-18       Impact factor: 17.367

Review 6.  Current siRNA targets in the prevention and treatment of intimal hyperplasia.

Authors:  Leena Pradhan-Nabzdyk; Chenyu Huang; Frank W LoGerfo; Christoph S Nabzdyk
Journal:  Discov Med       Date:  2014-09       Impact factor: 2.970

7.  SERCA2a gene transfer prevents intimal proliferation in an organ culture of human internal mammary artery.

Authors:  L Lipskaia; L Hadri; P Le Prince; B Esposito; F Atassi; L Liang; M Glorian; I Limon; A-M Lompre; S Lehoux; R J Hajjar
Journal:  Gene Ther       Date:  2012-07-05       Impact factor: 5.250

Review 8.  Leukotrienes as modifiers of preclinical atherosclerosis?

Authors:  Graziano Riccioni; Magnus Bäck
Journal:  ScientificWorldJournal       Date:  2012-05-01

9.  Serum Levels of IL-1 β , IL-6, TGF- β , and MMP-9 in Patients Undergoing Carotid Artery Stenting and Regulation of MMP-9 in a New In Vitro Model of THP-1 Cells Activated by Stenting.

Authors:  Rongrong Zhang; Fan Jiang; Cindy Si Chen; Tianzhu Wang; Jinzhou Feng; Tao Tao; Xinyue Qin
Journal:  Mediators Inflamm       Date:  2015-05-31       Impact factor: 4.711

Review 10.  Oximes: Novel Therapeutics with Anticancer and Anti-Inflammatory Potential.

Authors:  Igor A Schepetkin; Mark B Plotnikov; Andrei I Khlebnikov; Tatiana M Plotnikova; Mark T Quinn
Journal:  Biomolecules       Date:  2021-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.